Literature DB >> 22231616

Dabigatran: do we have sufficient data?: comment on "Dabigatran association with higher risk of acute coronary events".

Jeremy M Jacobs1, Jochanan Stessman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231616     DOI： 10.1001/archinternmed.2011.1721

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  3 in total

1.  Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.

Authors:  Kenneth W Mahaffey; Susanna R Stevens; Harvey D White; Christopher C Nessel; Shaun G Goodman; Jonathan P Piccini; Manesh R Patel; Richard C Becker; Jonathan L Halperin; Werner Hacke; Daniel E Singer; Graeme J Hankey; Robert M Califf; Keith A A Fox; Günter Breithardt
Journal:  Eur Heart J       Date:  2013-10-15       Impact factor: 29.983

Review 2.  What did we learn from new oral anticoagulant treatment?

Authors:  Charles T Esmon
Journal:  Thromb Res       Date:  2012-10       Impact factor: 3.944

Review 3.  Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.

Authors:  Andreas Clemens; Mandy Fraessdorf; Jeffrey Friedman
Journal:  Vasc Health Risk Manag       Date:  2013-10-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.